Genedx Holdings Corp. (WGS)
NASDAQ:WGS
Want to see WGS full AI Analyst Report?
WGS Stock Chart & Stats
$65.96
-$4.29(-4.42%)
At close: 4:00 PM EST
$65.96
-$4.29(-4.42%)
Day’s Range― - ―
52-Week Range$32.21 - $170.87
Previous CloseN/A
Volume338.68K
Average Volume (3M)1.71M
Market Cap
$1.58B
Enterprise Value$1.62B
Total Cash (Recent Filing)$170.69M
Total Debt (Recent Filing)$168.19M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 17, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding29,688,026
10 Day Avg. Volume1,336,539
30 Day Avg. Volume1,713,171
Financial Highlights & Ratios
PEG Ratio2.67
Price to Book (P/B)11.35
Price to Sales (P/S)8.18
P/FCF Ratio245.23
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue3.65
Enterprise Value/Gross Profit5.35
Enterprise Value/Ebitda-33.35
Forecast
1Y Price Target
$85.00Price Target Upside28.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.13
Revenue Forecast (FY)$478.38M
Bulls Say, Bears Say
Bulls Say
Robust Revenue & Volume GrowthStrong multi-year revenue growth (+354% TTM) and sustained test volume expansion (Q1 tests +34%) indicate durable market adoption across clinicians, NICU and pediatric channels. Scale supports fixed-cost absorption and commercial leverage, enabling structural margin improvement as volumes grow.
High Gross Margins & Unit EconomicsAdjusted gross margins near 69% reflect favorable unit economics for sequencing and interpretation services. Stable, high gross margins provide structural profit potential: once operating expenses are calibrated, these margins enable rapid operating leverage and sustained improvement in profitability.
Large Proprietary Genomic DatasetA contactable database with >2.5M patients and >1M exomes/genomes creates a durable competitive moat. This data advantage improves variant interpretation accuracy, payer engagement, and differentiation for clinical and biopharma partnerships, supporting long-term revenue and product leadership.
Bears Say
Persistent UnprofitabilityDespite top-line and gross margin gains, the company remains unprofitable (TTM net margin ~-17.6% and negative EBIT). Ongoing losses limit internally generated capital, increase financing dependence, and make durable profitability contingent on successful cost cuts and revenue-cycle execution.
Weak Cash Generation & Rising LeverageOperating cash flow turned negative in the TTM and free cash flow is materially negative after earlier improvement. Combined with increased leverage (debt/equity ~0.66), weaker cash conversion raises funding risk and constrains flexibility to invest in sales, R&D, or working capital without external financing.
Reimbursement & Mix Execution RiskLower-than-expected blended ARR and a ~12% revenue guide reduction highlight structural reimbursement and mix challenges. Genome reimbursement remains immature and ARR improvements require multiple quarters of payer coverage and revenue-cycle work, creating durable pressure on realized revenue per test and forecasting reliability.
GeneDx Holdings News
WGS FAQ
What was Genedx Holdings Corp.’s price range in the past 12 months?
Genedx Holdings Corp. lowest stock price was $32.21 and its highest was $170.87 in the past 12 months.
What is Genedx Holdings Corp.’s market cap?
Genedx Holdings Corp.’s market cap is $1.58B.
When is Genedx Holdings Corp.’s upcoming earnings report date?
Genedx Holdings Corp.’s upcoming earnings report date is Aug 17, 2026 which is in 74 days.
How were Genedx Holdings Corp.’s earnings last quarter?
Genedx Holdings Corp. released its earnings results on May 04, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.015 by -$0.265.
Is Genedx Holdings Corp. overvalued?
According to Wall Street analysts Genedx Holdings Corp.’s price is currently Undervalued.
Does Genedx Holdings Corp. pay dividends?
Genedx Holdings Corp. does not currently pay dividends.
What is Genedx Holdings Corp.’s EPS estimate?
Genedx Holdings Corp.’s EPS estimate is -0.19.
How many shares outstanding does Genedx Holdings Corp. have?
Genedx Holdings Corp. has 29,688,026 shares outstanding.
What happened to Genedx Holdings Corp.’s price movement after its last earnings report?
Genedx Holdings Corp. reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.015. Following the earnings report the stock price went down -49.198%.
Which hedge fund is a major shareholder of Genedx Holdings Corp.?
Currently, no hedge funds are holding shares in WGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GeneDx Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$85.00 (28.87% Upside)
$85.00 (28.87% Upside)
Blogger Sentiment
Bullish
WGS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 666.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $93.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.18%
12-Months-Change
Fundamentals
Return on Equity
-27.50%
Trailing 12-Months
Asset Growth
13.41%
Trailing 12-Months
Company Description
Genedx Holdings Corp.
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
WGS Company Deck
WGS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong operational momentum (34% volume growth, 27% exome/genome revenue growth, healthy ~69% adjusted gross margin, large proprietary dataset, new commercial products and expanded sales coverage) tempered by near-term execution and mix challenges (approximately $12M revenue shortfall in Q1 driven by lower blended ARR and $6.5M non-core misses), a significant Fabric impairment (~$31.3M), and a 12% reduction to prior full-year revenue expectations. Management laid out concrete remediation actions — tighter channel/revenue-cycle management, cost recalibration ($25M OpEx reduction), and focused commercial execution — and provided updated guidance that emphasizes line-of-sight growth and a pathway back to adjusted profitability in 2026, with further ARR improvement expected over multiple quarters as payer coverage and collections improve.View all WGS earnings summariesWGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
WGS Stock 12 Month Forecast
Average Price Target
$85.00
▲(28.87% Upside)
Technical Analysis
Evolent Health
―
10x Genomics
―
Certara
―
SOPHiA GENETICS
―
BrightSpring Health Services, Inc.
―
Ownership Overview
42.24% Insiders
24.60% Mutual Funds
17.89% Other Institutional Investors
2.11% Public Companies and
Individual Investors